Analysts Adjust Cadrenal Therapeutics, Inc. (CVKD) Valuation After Including CAD-1005 Program [Yahoo! Finance]
Cadrenal Therapeutics, Inc. (CVKD)
Company Research
Source: Yahoo! Finance
TheFly reported on April 7 that H.C. Wainwright reduced its price target on CVKD from $32 to $13 while maintaining a Buy rating. The adjustment reflects updated assumptions around share count and financing requirements, along with the inclusion of CAD-1005 in the firm's valuation model. The company also provided a recent update noting continued advancement of CAD-1005, including completion of its End-of-Phase 2 meeting with the U.S. Food and Drug Administration to define a potential Phase 3 registrational pathway. This analyst activity follows Cadrenal Therapeutics, Inc. (NASDAQ:CVKD)'s March 31 announcement of its fourth-quarter and full-year 2025 financial results, which provided critical context for the updated price target, along with a corporate update on its CAD-1005 program for heparin-induced thrombocytopenia and its broader 12-LOX inhibitor platform. The company reported continued progress, including completion of an End-of-Phase 2 meeting with the U.S. FDA on March 26, 20
Show less
Read more
Impact Snapshot
Event Time:
CVKD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CVKD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CVKD alerts
High impacting Cadrenal Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
CVKD
News
- Cadrenal Therapeutics Announces End-of-Phase 2 Meeting with the FDA and Pivotal Phase 3 Registration Path for CAD-1005 in Heparin-Induced Thrombocytopenia (HIT)GlobeNewswire
- Cadrenal Therapeutics (CVKD) had its price target lowered by HC Wainwright from $32.00 to $13.00. They now have a "buy" rating on the stock.MarketBeat
- Cadrenal Therapeutics Reports Fourth Quarter 2025 Financial Results; Provides Corporate Update on CAD-1005 Program for HIT Following End-of-Phase 2 FDA MeetingGlobeNewswire
- Cadrenal Therapeutics Highlights Research Supporting 12-LOX Inhibition in Reducing Inflammation in Obesity and Type 2 DiabetesGlobeNewswire
- Cadrenal Therapeutics Highlights Recent 12-LOX Inhibitor Platform Expansion [Yahoo! Finance]Yahoo! Finance
CVKD
Sec Filings
- 4/30/26 - Form 8-K
- 4/30/26 - Form EFFECT
- 4/29/26 - Form 424B3
- CVKD's page on the SEC website